HTML Microdata document

This HTML5 document contains 100 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
dcterms	http://purl.org/dc/terms/
yago-res	http://yago-knowledge.org/resource/
dbo	http://dbpedia.org/ontology/
foaf	http://xmlns.com/foaf/0.1/
n7	https://global.dbpedia.org/id/
dbt	http://dbpedia.org/resource/Template:
rdfs	http://www.w3.org/2000/01/rdf-schema#
n10	http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n13	http://commons.wikimedia.org/wiki/Special:FilePath/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
owl	http://www.w3.org/2002/07/owl#
wikipedia-en	http://en.wikipedia.org/wiki/
dbp	http://dbpedia.org/property/
dbc	http://dbpedia.org/resource/Category:
prov	http://www.w3.org/ns/prov#
xsdh	http://www.w3.org/2001/XMLSchema#
wikidata	http://www.wikidata.org/entity/
dbr	http://dbpedia.org/resource/

Statements

Subject Item: dbr:Propylpyrazoletriol
dbo:wikiPageWikiLink: dbr:ERA-63

Subject Item: dbr:ERA-45
dbo:wikiPageWikiLink: dbr:ERA-63

Subject Item: dbr:ERA-63
rdf:type: n10:ChemicalObject dbo:ChemicalSubstance owl:Thing dbo:Drug wikidata:Q8386
rdfs:label: ERA-63
rdfs:comment: ERA-63, also known as ORG-37663, as well as 3-methylene-7α-methyl-17α-ethynylestra-5(10)-en-17β-ol, is a synthetic, steroidal estrogen and a selective agonist of the ERα that was under development for the treatment of rheumatoid arthritis but was never marketed. The drug produced estrogenic effects but failed to show effectiveness for rheumatoid arthritis in a phase IIa clinical study. A large clinical trial also found that prinaberel (ERB-041), a selective ERβ agonist, was ineffective in the treatment of rheumatoid arthritis in spite of activity in preclinical models.
foaf:depiction: n13:ERA-63.svg
dcterms:subject: dbc:Ethynyl_compounds dbc:Synthetic_estrogens dbc:Estranes dbc:Vinylidene_compounds dbc:Abandoned_drugs
dbo:wikiPageID: 52740968
dbo:wikiPageRevisionID: 1123032865
dbo:wikiPageWikiLink: dbr:Preclinical_research dbc:Synthetic_estrogens dbc:Ethynyl_compounds dbr:Binding_selectivity dbr:Prinaberel dbr:Clinical_trial dbr:Phases_of_clinical_research dbr:Steroid dbc:Estranes dbr:Propylpyrazoletriol dbr:Agonist dbr:Rheumatoid_arthritis dbr:Methylpiperidinopyrazole dbc:Vinylidene_compounds dbr:Effectiveness dbr:Estrogen dbr:ERA-45 dbr:GTx-758 dbr:Synthetic_compound dbr:Animal_model dbc:Abandoned_drugs dbr:ERβ dbr:16α-LE2 dbr:ERα
owl:sameAs: n7:2d1MX wikidata:Q28209797 yago-res:ERA-63
dbp:wikiPageUsesTemplate: dbt:Genito-urinary-drug-stub dbt:Steroid-stub dbt:Estrogen_receptor_modulators dbt:Reflist dbt:Short_description dbt:Drugbox
dbo:thumbnail: n13:ERA-63.svg?width=300
dbp:c: 22
dbp:chemspiderid: 8058857
dbp:h: 30
dbp:iupacName: -17
dbp:o: 1
dbp:pubchem: 87921126
dbp:smiles: C[C@@H]1CC2=C[C@@H]3[C@@H]1[C@@H]4CC[C@]O
dbp:stdinchi: 1
dbp:stdinchikey: ITYURVXIFIQGDB-LADQHVHVSA-N
dbp:synonyms: 3
dbp:width: 225
dbo:abstract: ERA-63, also known as ORG-37663, as well as 3-methylene-7α-methyl-17α-ethynylestra-5(10)-en-17β-ol, is a synthetic, steroidal estrogen and a selective agonist of the ERα that was under development for the treatment of rheumatoid arthritis but was never marketed. The drug produced estrogenic effects but failed to show effectiveness for rheumatoid arthritis in a phase IIa clinical study. A large clinical trial also found that prinaberel (ERB-041), a selective ERβ agonist, was ineffective in the treatment of rheumatoid arthritis in spite of activity in preclinical models.
prov:wasDerivedFrom: wikipedia-en:ERA-63?oldid=1123032865&ns=0
dbo:wikiPageLength: 4581
dbo:pubchem: 87921126
foaf:isPrimaryTopicOf: wikipedia-en:ERA-63

Subject Item: dbr:16α-LE2
dbo:wikiPageWikiLink: dbr:ERA-63

Subject Item: dbr:GTx-758
dbo:wikiPageWikiLink: dbr:ERA-63

Subject Item: dbr:C22H30O
dbo:wikiPageWikiLink: dbr:ERA-63

Subject Item: dbr:Estrogen_receptor_alpha
dbo:wikiPageWikiLink: dbr:ERA-63

Subject Item: dbr:Org-37,663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:Org-37663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:Org37,663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:Org37663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:Org_37,663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:Org_37663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:ERA63
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:ERA_63
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:ORG-37,663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:ORG-37663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:ORG37,663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:ORG37663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:ORG_37,663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: dbr:ORG_37663
dbo:wikiPageWikiLink: dbr:ERA-63
dbo:wikiPageRedirects: dbr:ERA-63

Subject Item: wikipedia-en:ERA-63
foaf:primaryTopic: dbr:ERA-63